Welcome to the first edition of our European Healthcare & Life Sciences Market Update, a new report summarising key emerging trends, opportunities, and challenges facing the market in 2022. During the last 12 months, the European healthcare and life sciences market has thrived while in the throes of the Brexit transition and the COVID-19 pandemic and vaccine rollout, showing remarkable growth in M&A and venture capital activity, attracting a fresh crop of global investors, and channeling increased funding into UK digital health.

As new investors approach the market - attracted by the booming biotech and life sciences sector, Europe’s wave of innovation, public and private investment in digital health, and a growing pipeline of pharma carve-outs - dealmakers must stay alert to increasing global regulatory scrutiny. In this edition, amongst myriad regulatory changes faced by the European life sciences industry, we scrutinise the practical implications pharmaceutical companies in Europe and overseas should be aware of now that the EU Clinical Trials Regulation has finally come into effect.